The Initiative for Medicines, Access, and Knowledge (I-MAK) report notes that 89% of these applications were filed in the United States after Humira was already on the market, and 49% were filed after the first patent expired in 2014.
The Initiative for Medicines, Access, and Knowledge (I-MAK) recently released a case study on AbbVie’s brand name adalimumab (Humira), the world’s highest-selling drug.
According to I-MAK, drug makers of the 12 top-selling medicines have sought, on average, “38 years of attempted monopoly protection through patents and patent applications.” The report noted that among these top 12 best-selling medicines, without the threat of competition, all but 1 has increased in price.
For Humira specifically, development began in 1993 through a joint venture, with initial patents filed in 1994. The biologic was subsequently approved by the FDA in 2002. To date, Humira is covered by 247 total patent applications in the United States. The report notes that 89% of these applications were filed in the United States after Humira was already on the market, and 49% were filed after the first patent expired in 2014.
Click here to read more about Humira’s patent estate.
Comparatively, the number of patent applications filed on Humira to date at the European Patent office is only 76. “What is noticeable from the European Patent Office data compared to the [United States] is that a number of AbbVie’s patent applications after 2002 that would have significantly extended its monopoly were either withdrawn, refused during examination, or revoked after patent challenges,” said the report.
Just last year, Humira generated $18 billion in global sales—$12 billion of which came from US payers. For Medicare and Medicaid specifically, from 2012-2016, taxpayers spent a total of $9.2 billion on Humira. “If Humira were a standalone company, it would be larger than many Fortune 500 companies, including Visa, General Mills, and Monsanto.”
Though the first biosimilar adalimumab is not set to hit the US market until 2023, Europe will be feeling the benefits of a lower cost option much sooner as the first biosimilar will be made available next month. The report notes that, even after these products are brought to market, the developers will have to pay royalties to license AbbVie’s Humira patents. Typically, the cost of these royalties are “likely to be passed down to the consumer.”
I-MAK closed its report by calling for the US Patent and Trademark Office and Congress to hold hearings and invite public comments on pharmaceutical patenting practices and their impact on drug prices for payers and patients in America.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.